Press release content from Business Wire. The AP news staff was not involved in its creation.
Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use
February 3, 2021 GMT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 3, 2021--
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Singapore Health Sciences Authority (HSA) has approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR).
ADVERTISEMENT
“Today’s authorization is another important step in the global fight against COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I want to thank the Singapore Ministry of Health and the HSA for their collaboration and for the confidence they have demonstrated in COVID-19 Vaccine Moderna with this decision.”